NVIDIA · Video summary
NVIDIA & Eli Lilly: The AI Revolution in Drug Discovery | Jensen Huang & David Ricks
NVIDIA and Eli Lilly are harnessing AI and accelerated computing to revolutionize drug discovery and biomedical research, aiming to address humanity's biggest challenges.
Watch on YouTube ↗Key takeaways
- 🎯Co-designing algorithms, hardware, and software accelerates application development far beyond Moore's law predictions.00:25
- 🚀Invest in developing integrated infrastructure that combines hardware, algorithms, and workflows for breakthrough AI applications.00:48
- 💡Rapid advancements in AI, especially multimodality and reasoning, are transforming self-driving cars and medical diagnostics.03:55
- 📈Creating infrastructure for AI research, like supercomputers, attracts top scientists and accelerates breakthroughs in biology and healthcare.17:00
- 🌟Building comprehensive AI platforms for biomedical data enables a scientific flywheel of data generation, model training, and experimentation.22:00
- 🧬Leverage AI and supercomputing to accelerate biomedical research, focusing on predictive models for proteins, molecules, and diseases.23:00
Chapters
- 0:04🎤 Introduction and Overview of Accelerated Computing
- 1:02🚀 AI Advancements and Impact
- 2:02🎮 Breakthroughs in Computer Graphics
- 3:00🚗 Self-Driving Cars and Reasoning Capabilities
- 7:48🔬 NVIDIA’s Platform and Achievements in Biology
- 8:42💊 AI in Drug Discovery and Protein Design
- 9:29🧬 Partnership in Life Sciences and Drug Discovery
- 16:02🤝 Future of Pharmaceutical Innovation
- 19:16🏢 Building a Dedicated Biology Supercomputer in Indianapolis
- 22:53🌍 AI and Biology as a Revolution
- 29:16💥 Transformative Potential of AI and Future Horizons
- 33:28🧠 Using AI for Brain Health and Addiction
The digest
A groundbreaking dialogue between NVIDIA’s Jensen Huang and Eli Lilly’s David Ricks reveals how advances in AI and accelerated computing are transforming pharmaceutical research and drug development into a faster, more precise engineering discipline, promising profound impact on human health.
High-Level Overview
This presentation explores the intersection of accelerated computing and life sciences, illustrating how NVIDIA’s decades-long innovation in co-designed computing architectures has culminated in AI breakthroughs that can revolutionize drug discovery. Eli Lilly, a global pharmaceutical pioneer, shares its journey from empirical and slow innovation cycles to deploying AI-powered methods to speed invention and diversify drug pipelines. The collaboration between NVIDIA and Lilly defines a new blueprint for the future, leveraging supercomputing, AI models, and large-scale data generation to unlock the complexity of human biology. This is essential viewing for professionals in biotechnology, AI, and healthcare innovation aiming to understand AI’s concrete roles in accelerating lifesaving therapies.
Keep reading in The Digest
The full 6-minute article, 10 more sections, and every new episode from NVIDIA and the creators you follow.
- Structured Deep Dive
- 1. The Power of Accelerated Computing (0:04–6:00)
- 2. NVIDIA’s Life Sciences Platforms and AI Models (6:00–9:00)
- 3. Eli Lilly’s R&D Transformation and Strategic Vision (10:00–18:00)
- 4. The Partnership: Building the World’s Largest On-Prem Biology Supercomputer and AI Drug Discovery Lab (18:00–23:30)
- 5. From Empiricism to Engineering in Drug Discovery (23:30–29:30)
- 6. GLP1 and the Future of Therapeutics (29:30–37:48)
- Key Framework: The AI Drug Discovery “Multi-Layer Cake”
- Practical Implications & Takeaways
- Action-Oriented Summary
More from NVIDIA
Advancing Infrastructure for the Era of Agentic AI | Ian Buck at AI Infra Summit 2026
NVIDIA's Ian Buck discusses the evolution of AI infrastructure, highlighting the shift towards agentic AI and the full-stack Vera Rubin platform designed to meet its demanding computational needs.
The Infrastructure of Intelligence: NVIDIA and OpenAI on a Decade of Building Frontier AI
The AI Infra Summit brought together industry leaders to discuss the challenges and innovations in building AI infrastructure at scale. The conversation delved into the evolving definition of scale, the complexities of designing compute token factories, and the pivotal role of partnerships in navigating this unprecedented growth.
How Mistral Is Building Frontier AI for the Enterprise | NVIDIA AI Podcast Ep. 301
In this episode of the NVIDIA AI Podcast, Tim Lacroix, co-founder and CTO of Mistral AI, discusses the company's commitment to open source models, their collaboration with NVIDIA, and the development of their new platform, Mistral Forge, aimed at enhancing enterprise AI solutions. Lacroix emphasizes the importance of customization in AI to meet specific industry needs while fostering global innovation.
NVIDIA GTC 2026: Healthcare Special Address
In this NVIDIA GTC 2026 address, NVIDIA discusses the transformative impact of AI in healthcare, highlighting advancements in digital labs, agentic AI, and robotics that enhance disease understanding, drug discovery, and patient care. The presentation emphasizes collaboration and the integration of AI technologies to create a more efficient and accessible healthcare system.
Automotive Special Address: Advancing Level 4 Autonomy, the Path to Scalable, Safe AVs and Robotaxis
NVIDIA's Drive AV platform is evolving with physical AI and a three-computer architecture (training, simulation, inference) to accelerate Level 4 autonomy through hardware, software, and open-sourced models.
NVIDIA GTC 2026 Open Models Panel Highlights with Jensen Huang
AI is evolving beyond single models to complex systems and agents, with open models playing a crucial role in driving innovation, customization, and trust, especially for mission-critical applications.